References
Kawachi I. PharmacoEconomics 2: 324–334, 1992
Stason WB. Hypertension 13 (Suppl. I): I–145–I–148, 1989
Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet 1: 185–191, 1982
MacMahon S, et al. Lancet 335: 765–774, 1990
Johannesson M, et al. Health Policy 18: 141–150, 1991
Pickering TJ, et al. JAMA 259: 225–228, 1988
Kawachi I, Malcolm LA. J Cardiovasc Pharmacol 16 (Suppl. 7): S126–S128, 1990
Edelson JT, et al. JAMA 263: 408–413, 1990
Kawachi I, Malcolm LA. J Hypertens 9: 199–208, 1991
Littenberg B, et al. Ann Intern Med 112: 192–202, 1991
Kaplan NM. PharmacoEconomics 1: 303–305, 1992
Herxheimer A. Lancet 337: 346–348, 1991
Maling TJB, Kawachi I. N Z Med J 103: 231–233, 1990
Pharmaceutical Business News: 9, 26 Oct 1992
Schmieder RE, et al. JAMA 265: 1566–1571, 1991
Rights and permissions
About this article
Cite this article
Cost Effectiveness of Antihypertensive Treatment. Drugs Ther. Perspect 1, 15–16 (1993). https://doi.org/10.2165/00042310-199301050-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199301050-00007